EXPAREL
Peakbupivacaine
NDAINJECTIONINJECTABLE, LIPOSOMAL
Approved
Oct 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
EXPAREL (bupivacaine) is nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 2011.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXPAREL is a liposomal formulation of bupivacaine, an amide local anesthetic approved in 2011 for infiltration anesthesia via injection. It works by slowing nerve impulse propagation and reducing the rate of rise of the action potential, providing prolonged local anesthesia by blocking pain, temperature, and touch sensation in a predictable sequence. Patients receiving EXPAREL are those undergoing surgical procedures requiring extended local or regional anesthesia.
Peak17.7 years to LOE
EXPAREL is in peak commercial stage with strong patent protection extending to 2044, suggesting stable team size and focused defense against generic/competitive erosion.
Mechanism of Action
nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is…
Pharmacologic Class:
Amide Local Anesthetic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Smart Knee Evaluation of Exparel and Zynrelef in TKA Recovery
Started Oct 2026
200 enrolled
Total Knee Anthroplasty
Comparison of Analgesic Efficacy of Intrathecal Bupivacaine Versus Bupivacaine Plus Dexmedetomidine in Patients Undergoing Orthopedic Surgeries.
Started Aug 2026
80 enrolled
Postoperative PainPainOrthopaedic Surgery+1 more
Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
Started Jan 2026
200 enrolled
Pain Management
Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.
Started Jul 2025
408 enrolled
Anal Fistula
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Started Oct 2024
200 enrolled
Breast Cancer
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.